Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- PMID: 30207593
- DOI: 10.3322/caac.21492
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Erratum in
-
Erratum: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J Clin. 2020 Jul;70(4):313. doi: 10.3322/caac.21609. Epub 2020 Apr 6. CA Cancer J Clin. 2020. PMID: 32767693 No abstract available.
Abstract
This article provides a status report on the global burden of cancer worldwide using the GLOBOCAN 2018 estimates of cancer incidence and mortality produced by the International Agency for Research on Cancer, with a focus on geographic variability across 20 world regions. There will be an estimated 18.1 million new cancer cases (17.0 million excluding nonmelanoma skin cancer) and 9.6 million cancer deaths (9.5 million excluding nonmelanoma skin cancer) in 2018. In both sexes combined, lung cancer is the most commonly diagnosed cancer (11.6% of the total cases) and the leading cause of cancer death (18.4% of the total cancer deaths), closely followed by female breast cancer (11.6%), prostate cancer (7.1%), and colorectal cancer (6.1%) for incidence and colorectal cancer (9.2%), stomach cancer (8.2%), and liver cancer (8.2%) for mortality. Lung cancer is the most frequent cancer and the leading cause of cancer death among males, followed by prostate and colorectal cancer (for incidence) and liver and stomach cancer (for mortality). Among females, breast cancer is the most commonly diagnosed cancer and the leading cause of cancer death, followed by colorectal and lung cancer (for incidence), and vice versa (for mortality); cervical cancer ranks fourth for both incidence and mortality. The most frequently diagnosed cancer and the leading cause of cancer death, however, substantially vary across countries and within each country depending on the degree of economic development and associated social and life style factors. It is noteworthy that high-quality cancer registry data, the basis for planning and implementing evidence-based cancer control programs, are not available in most low- and middle-income countries. The Global Initiative for Cancer Registry Development is an international partnership that supports better estimation, as well as the collection and use of local data, to prioritize and evaluate national cancer control efforts. CA: A Cancer Journal for Clinicians 2018;0:1-31. © 2018 American Cancer Society.
Keywords: cancer; epidemiology; incidence; survival.
© 2018 American Cancer Society.
Comment in
-
Oesophageal cancer: risks, prevention, and diagnosis.BMJ. 2019 Sep 6;366:l5391. doi: 10.1136/bmj.l5391. BMJ. 2019. PMID: 31492677 No abstract available.
Similar articles
-
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J Clin. 2024 May-Jun;74(3):229-263. doi: 10.3322/caac.21834. Epub 2024 Apr 4. CA Cancer J Clin. 2024. PMID: 38572751
-
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4. CA Cancer J Clin. 2021. PMID: 33538338
-
The Global Burden of Cancer 2013.JAMA Oncol. 2015 Jul;1(4):505-27. doi: 10.1001/jamaoncol.2015.0735. JAMA Oncol. 2015. PMID: 26181261 Free PMC article.
-
Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018.Eur J Cancer. 2018 Nov;103:356-387. doi: 10.1016/j.ejca.2018.07.005. Epub 2018 Aug 9. Eur J Cancer. 2018. PMID: 30100160 Review.
-
Cancer in sub-Saharan Africa in 2020: a review of current estimates of the national burden, data gaps, and future needs.Lancet Oncol. 2022 Jun;23(6):719-728. doi: 10.1016/S1470-2045(22)00270-4. Epub 2022 May 9. Lancet Oncol. 2022. PMID: 35550275 Review.
Cited by
-
Associations of the Healthy Beverage Index (HBI) and the risk of Breast Cancer (BrCa): a case-control study.BMC Womens Health. 2024 Oct 26;24(1):573. doi: 10.1186/s12905-024-03411-6. BMC Womens Health. 2024. PMID: 39462378 Free PMC article.
-
BUB1 as a novel marker for predicting the immunotherapy efficacy and prognosis of breast cancer.Transl Cancer Res. 2024 Sep 30;13(9):4534-4554. doi: 10.21037/tcr-24-704. Epub 2024 Sep 27. Transl Cancer Res. 2024. PMID: 39430818 Free PMC article.
-
Global strategy for prevention of gastric cancer.World J Clin Cases. 2024 Oct 26;12(30):6353-6357. doi: 10.12998/wjcc.v12.i30.6353. World J Clin Cases. 2024. PMID: 39464323 Free PMC article.
-
PGRMC1 and PAQR4 are promising molecular _targets for a rare subtype of ovarian cancer.Open Life Sci. 2024 Oct 26;19(1):20220982. doi: 10.1515/biol-2022-0982. eCollection 2024. Open Life Sci. 2024. PMID: 39464509 Free PMC article.
-
Prehabilitation in Frail Octogenarian and Nonagenarian Patients in Colorectal Cancer Surgery: Short- and Medium-Term Outcomes.J Clin Med. 2024 Oct 14;13(20):6114. doi: 10.3390/jcm13206114. J Clin Med. 2024. PMID: 39458064 Free PMC article.
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical